Meeting
2020 ASCO Virtual Scientific Program
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.
Presenter
Huiping Li, MD
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1059)
DOI
10.1200/JCO.2020.38.15_suppl.1059
Abstract #
1059
Poster Bd #
144
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2020 ASCO Virtual Scientific Program
The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive metastatic breast cancer.
Speaker: Saya Jacob, MD
Videos & Slides
2024 ASCO Annual Meeting
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
Speaker: Toshinari Yamashita, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC).
Speaker: D. Ross Camidge, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).
Speaker: lorenza Palmero, MD